癌症研究
黑色素瘤
免疫系统
肿瘤微环境
免疫疗法
下调和上调
生物
免疫学
细胞毒性T细胞
肿瘤进展
癌症免疫疗法
抑制器
髓样
免疫耐受
髓源性抑制细胞
医学
免疫
信号转导
转录组
先天免疫系统
串扰
免疫检查点
CD8型
T细胞
细胞
恶性转化
炎症
调解人
癌症
基因
作者
Paula Granado‐Martínez,Kimberley McGrail,Roberto Orsenigo,Ginevra Caratù,Paula Nieto,Yuxin Ding,Ángel R. Nebreda,Juan Martín‐Caballero,Iván Ortega,Herena Eixarch,Carmen Espejo,Adrià Molero-Valenzuela,Javier Hernández‐Losa,Berta Ferrer Fábrega,Holger Heyn,Eva Muñoz‐Couselo,Vicente García‐Patos,Juan A. Recio
标识
DOI:10.1038/s41467-026-77868-4
摘要
Understanding how tumor cells shape the tumor microenvironment (TME) and evade the host immune response is critical for developing novel therapeutic combinations. In this study, we identify tumor cell p38α as a therapeutic target that restricts antitumor immunity and contributes to resistance against immune-checkpoint inhibitors (ICIs). Genetic analyses of mouse and human melanomas reveal alterations in the mitogen-activated protein kinase (MAPK)-stress pathway, including upregulation of MAPK14. We demonstrate a dual role for p38α in ultraviolet-B (UVB)-induced Braf V600E melanoma, acting as a tumor suppressor during melanocyte transformation but promoting melanoma growth and progression. Mechanistically, p38α impairs cytotoxic immune responses, modulates immunosuppressive myeloid cells, and regulates inflammatory mediators that shape the TME. Loss or inhibition of p38α enhances and restores sensitivity to PD-1 blockade, resulting in tumor regression and improved overall survival. Moreover, a p38α-associated gene signature correlates with favorable immunotherapy outcomes in patients with melanoma, underscoring its translational relevance. The role of p38 activation in melanoma remains controversial. Here the authors report that, in an UVB induced Braf V600E-mutated spontaneous mouse melanoma model, p38α contributes to tumor fitness and anti-tumor immune responses, showing that p38α inhibition sensitizes tumors to anti-PD1.
科研通智能强力驱动
Strongly Powered by AbleSci AI